Standort in Deutschland, wo man günstige und qualitativ hochwertige Kamagra Ohne Rezept Lieferung in jedem Teil der Welt zu kaufen.

Kaufen priligy im Online-Shop. Wirkung ist gut, kommt sehr schnell, innerhalb von 5-7 Minuten. priligy was nur nicht versucht, verbrachte eine Menge Geld und Nerven, und geholfen hat mir nur dieses Tool.

Brustambulanz.info

PUBLIKATIONSLISTE
Rupert Bartsch
2010 Impact Factor (IF) 185,607
Total Cites (September 2011): 381


ORIGINALARBEITEN


Erstautor
Corresponding
Author IF
1. BARTSCH R, FROMM S, RUDAS M, WENZEL C, HARBAUER S, ROESSLER K, KITZ K, STEGER GG, WEITMANN HD, POETTER R, ZIELINSKI CC, DIECKMANN K. Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer. Radiother 2. BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, BACHLEITNER-HOFFMANN T, LOCKER GJ, RUDAS M, MADER R, ZIELINSKI CC, STEGER GG. Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. Breast 3. BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, MADER RM, GNANT M, JAKESZ R, RUDAS M, ZIELINSKI CC, STEGER GG. Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clin 4. BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, RUDAS M, MADER RM, GNANT M, ZIELINSKI CC; STEGER GG. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J
5. BARTSCH R, MLINERITSCH B, GNANT M, NIERNBERGER T, PLUSCHNIG U,
GREIL R, WENZEL C, SEVELDA P, THALER J, RUDAS M, POBER M, ZIELINSKI
CC, STEGER GG, on behalf of the Austrian Fulvestrant Registry.
The Austrian fulvestrant registry - results from a prospective observation of fulvestrant
in postmenopausal patients with metastatic breast cancer.
Breast Cancer Res Treat 2009;115:373-80.

IF 4,859

6. BARTSCH R, BERGHOFF A, PLUSCHNIG U, BAGO-HORVATH Z, DUBSKY P,
ROTTENFUSSER A, DEVRIES C, RUDAS M, FITZAL F, DIECKMANN K, GNANT
M, MADER RM, ZISLINSKI C, STEGER GG.
Impact of Anti-Her2 therapy on overall survival in HER2-overexpressing breast cancer
patients with brain metastases.
British Journal of Cancer 2011;[Epub ahead of print].

IF 4,831
Sonstige
1. BARTSCH R, WENZEL C, SEVELDA U, HUSSIAN D, PLUSCHNIG U, LOCKER GJ, MADER R, ZIELINSKI CC, STEGER GG. Darbepoetin alfa as treatment for anaemia in patients receiving chemotherapy: a single-centre experience. Anticancer 2. BARTSCH R, WENZEL C, PLUSCHNIG U, HUSSIAN D, SEVELDA U, LOCKER GJ, MADER R, ZIELINSKI CC, STEGER GG. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer 3. BARTSCH R, WEITMANN HD, PENNWIESER W, WENZEL C, MUSCHITZ S, BALDASS M, ROESSLER K, HASSLER M, MAROSI C, POETTER R, DIECKMANN K. Retrospective analysis of re-irradiation in malignant glioma: a single-center experience. Wien 4. BARTSCH R, WENZEL C, HUSSIAN D, PLUSCHNIG U, SEVELDA U, KOESTLER W, ALTORJAI G, LOCKER GJ, MADER R, ZIELINSKI CC, STEGER GG. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC 5. BARTSCH R, WENZEL C, PLUSCHNIG U, HUSSIAN D, SEVELDA U, LOCKER GJ, MADER R, ZIELINSKI CC, STEGER GG. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment BMC 6. BARTSCH R, WOEHRER S, RADERER M, HEJNA M. Serum Interleukin-6 levels in patients with stage I MALT-lymphoma compared to gastric and pancreatic cancer. Anticancer 7. BARTSCH R, ROTTENFUSSER A, WENZEL C, DIECKMANN K, PLUSCHNIG U, ALTORJAI G, RUDAS M, MADER RM, POETTER R, ZIELINSKI CC, STEGER GG. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J
8. BARTSCH R, STEGER GG, FORSTNER B, WENZEL C, PLUSCHNIG U, RIZOVSKI
B, ZIELINSKI CC, MADER RM.
Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is
not increased by paclitaxel.
BMC

9. BARTSCH R, WENZEL C, GAMPENRIEDER S, PLUSCHNIG U, ALTORJAI G,
RUADS M, MADER RM, DUBSKY P, ROTTENFUSSER A, GNANT M, ZIELINSKI
CC, STEGER GG.

Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with
metastatic breast cancer.
Cancer Chemoth Pharmacol 2008;62:903-10.

IF
2,759

10. BARTSCH R, DE VRIES C, PLUSCHNIG U, DUBSKY P, HORVATH Z,
GAMPENRIEDER SP, RUDAS M, MADER RM, ROTTENFUSSER A, WILTSCKE C,
GNANT M, ZIELINSKI CC, STEGER GG.
Predicting time to progression and response to second-line trastuzumab-based therapy
in Her2-positive advanced breast cancer.
BMC

Cancer
2009;9:367.
IF
3,153
1. WOEHRER S, STREUBEL B, BARTSCH R, CHOTT A, RADERER M. Monoclonal immunoglobulin production is a frequent event in patients with MALT Lymphoma. Clin 2. RADERER M, WOEHRER S, BARTSCH R, PRAGR G, DRACH J, HEJNA M, GAIGER A, TURETSCHEK K, JAEGER U, STREUBEL B, ZIELINSKI CC. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J 3. STEGER GG, BARTSCH R, WENZEL C, PLUSCHNIG U, LOCKER GJ, HUSSIAN D, SEVELDA U, ZIELINSKI CC. Fulvestrant (“Faslodex”) in pre-treated patients with advanced breast cancer: A single-centre experience. Eur 4. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, ALTORJAI G, ZIELINSKI CC, LANG A, HAID A, JAKESZ R, GNANT M, STEGER GG. Invasiv ductal carcinoma and lobular of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast
5. DUBSKY P, SEVELDA P, JAKESZ R, HAUSMANINGER H, SAMONIGG H,
SEIFERT M, DENISON U, MLINERITSCH B, STEGER G, KWASNY W, STÖGER J,
BARTSCH R, STIERER M, TAUCHER S, FRIDRIK M, SCHIPPINGER W, GREIL
R, PÖTTER R, GNANT M for the Austrian Breast and Colorectal Cancer Study Group.
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal
primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-
fluorouracil chemotherapy.
Clin

Cancer
Res
2008;14:2082-87.
IF
7,338

6. TOMOVA A, BARTSCH R, BRODOWICZ T, TZEKOVA V, TIMCHEVA C,
WILTSCHKE C, GERGES DA, PAWLEGA J, SPANIK S, INBAR M, ZIELINSKI CC.
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by
gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable

breast cancer patients: A prospective multicentre trial of the Central European
Cooperative Oncology Group (CECOG).
Breast

Cancer
Res
Treat
2010;169-76.
IF
4,859

7. WIEDERMANN U, WILTSCHKE C, JASINSKA J, KUNDI M, ZURBRIGGEN R,
GARNER-SPITZER E, BARTSCH R, STEGER G, PEHAMBERGER H, SCHEINER
O, ZIELINSKI CC.
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific
immune responses in patients with metastatic breast cancer: a phase I study.
Breast

Cancer
Res
Treat
2010;119:673-83.
IF
4,859

8. MICHLMAYR A, BACHLEITNER-HOFMANN T, BAUMANN S, MARCHETTI-
DESCHMANN M, RECH-WEICHSELBRAUN I, BURGHUBER C, PLUSCHNIG U,
BARTSCH R, GRAF A, GREIL R, STEGER G, GNANT M, BERGMANN M,
OEHLER R.
Modulation of plasma complement by the initial dose of epirubicin/docetaxel
combination therapy in breast cancer and its predictive value.
Br

J
Cancer
2010;103:1201-1208.
IF
4,831

9. FITZAL F, RIEDL O, MITTLBÖCK M, DUBSKY P, STEGER G, BARTSCH R,
JAKESZ R, GNANT M.
Oncologic safety of breast conserving surgery after tumor downsizing by neoadjuvant
therapy: A retrospective single centre cohort study.
Breast

Cancer
Res
Treat
2011;127:121-8.
IF
4,859

10. FITZAL F, MITTLBOECK M, STEGER G, BARTSCH R, RUDAS M, DUBKSY P,
RIEDL O, JAKESZ R, GNANT M.
Neoadjuvant Chemotherapy Increases the Rate of Breast Conservation in Lobular-Type
Breast Cancer Patients:
Ann Surg Oncol 2011;[Epub ahead of print]

IF 4,182

11. DUBSKY P, JAKESZ R, MLINERITSCH B, PÖSTLBERGER S, SAMONIGG H,
KWASNY W, TAUSCH C, STÖGER H, HAIDER K, FITZAL F, SINGER CF,
STIERER M, SEVELDA P, LUSCHIN-EBENGREUTH G, TAUCHER S, RUDAS M,
BARTSCH R, STEGER G, GREIL R, FILIPCIC L, GNANT M, on behalf of the
ABCSG.
Tamoxifen and anastrozole as a sequencing strategy: A randomized controlled trial in
3714 postmenopausal patients with endocrine responsive early breast cancer from the
Austrian Breast and Colorectal Cancer Study Group.
J

Clin
Oncol
2011;[in
press]
IF
18,970

Sonstige
1. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, ZIELINSKI CC, STEGER GG. Capecitabine-monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Anticancer 2. STEGER GG, WENZEL C, BARTSCH R, RUDAS M, GNANT M, ZIELINSKI CC, JAKESZ R. Preliminary results of a pilot-trial with trastuzumab + weekly epidoxorubicin/docetaxel in the neoadjuvant treatment of primary, operable breast cancer Breast 3. WENZEL C, HUSSIAN D, BARTSCH R, PLUSCHNIG U, LOCKER GJ, RUDAS M, GNANT M, JAKESZ R, ZIELINSKI CC, STEGER GG. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 2004;12:678-81. 4. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHING U, LOCKER GJ, SEVELDA U, ZIELINSKI CC, STEGER GG. Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome. Support 5. WENZEL C, LOCKER GJ, BARTSCH R, PLUSCHNIG U, HUSSIAN D, ZIELINSKI CC, STEGER GG. Preoperative second-line chemotherapy induces objective responses in primary breast cancer. Wien 6. WOEHRER S, BARTSCH R, HAJNA M, DRACH J, RADERER M. Routine application of the proton pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy Scand 7. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, SEVELDA U, ZIELINSKI CC, STEGER GG. Preoperative therapy with epidoxorubicin/docetaxel/capecitabine plus pegfilgrastim (TEX + P) in primary breast cancer: a pilot study. Anticancer
8. FROMM S, BARTSCH R, RUDAS M, WENZEL C, DE VRIES A, STEGER GG,
ZIELINSKI CC, POETTER R, DIECKMANN K.
Time to development of brain metastases in breast cancer: a retrospective analysis of
risk factors.
Breast

2008;17:512-6. IF
2,089

9. FROMM-HAIDENBERGER S, POHL G, WIDDER J, KREN G, FITZAL F,
BARTSCH R, DE VRIES J, ZIELINSKI C, PÖTTER R.
Vienna International Summer School on Experimental and Clinical Oncology for
medical students: an Austria cancer education project.
J

Cancer
Educ
2010;25:51-4. IF
0,682

10. KIERNER KA, GARTNER V, BARTSCH R, HLADSCHIK-KERNER B, GRUBER
A, HASSLER M, WATZKE HH.
Attitudes towards palliative care in primary metastatic cancer: a survey among
oncologists.
Wien

Klin
Wochenschr
2010;122:45-9.
IF
0,747

11. GAMPENRIEDER SP, BARTSCH R, PLUSCHNIG U, MATZNELLER P,
SCHEUER R, DUBSKY P, GNANT M, ZIELINSKI CC, STEGER GG.

Capecitabine and vinorelbine as an all-oral chemotherapy in Her2-negative locally
advanced and metastatic breast cancer.
Breast

Care
2010;5:158-62.
IF
0,364

12. FIEGL M, MLINERITSCH B, HUBALEK M, BARTSCH R, PLUSCHNIG U,
STEGER GG.
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic
breast cancer: results of an Austrian observational trial.
BMC

Cancer
2011;11:373.
IF
3,153

SONSTIGE
PUBLIKATIONEN
1. BARTSCH R. Comment on the letter to the editor „Hormone receptor status as an independent variable affecting the survival of advanced breast cancer patients with brain metastases“ (Hakan Harputluoglu et al.). Letter to the editor Radiother 2. BARTSCH R, WENZEL C, ZIELINSKI CC, STEGER GG. Her-2 positive breast cancer: hope beyond trastuzumab. Review Bio Drugs 3. BARTSCH R, WENZEL C, STEGER GG. Trastuzumab in the management of early and advanced stage breast cancer. Review Biologics
4. BARTSCH R, STEGER GG.
Adjuvant chemotherapy in breast cancer.
Review
Magazine of European Medical Oncology

2008;1:91-8.
IF
n.a.

5. BARTSCH R, STEGER GG.
The role of supportive therapy in the era of modern adjuvant treatment – current and
future tools.
Review
Breast

Care
2009;4:167-76.
IF
0,364

6. BARTSCH R, STEGER GG.
Role of denosumab in breast cancer.
Review
Expert

Opin
Biol
Ther
2009;9:1255-33.
IF
n.a.

7. BARTSCH R, STEGER GG.
Metastatic breast cancer: review on chemotherapy.
Review (German)
Senologie

2009;6:231-6.
IF
n.a.

8. BARTSCH R, ZIEBERMAYR R, ZIELINSKI CC, STEGER GG.

Triple negative breast cancer.
Review
Wien

Med
Wochenschr
2010;160:174-81.
IF
n.a.

9. BARTSCH R, STEGER GG, ZIELINSKI CC, ZIEBERMAYR R.
Breast Cancer: Rank-ligand inhibition.
Review
Breast

Care
2010;5:320-5.
IF
0,364

10. BARTSCH R, ZIEBERMAYR R.
ASCO 2010: update on metastatic breast cancer.
Review
Magazine of European Medical Oncology

2010;3:159-62. IF
n.a.

11. STEGER GG, BARTSCH R.
Denosumab for the treatment of bone metastases in breast cancer: Evidence and
opinion.
Review
Ther

Adv
Med
Oncol
2011;3:233-243.
IF
n.a.

12. BARTSCH R, STEGER GG.
Mammakarzinom
Review (German)
Wien Klin Wochenschr Educational 2011;[in press].

IF 0,747

13. BARTSCH R, DUBSKY PC, LOIBL S, STEGER GG.
Opinions on the ASCO 2011 Annual Meeting
Expert Panel
Breast

Care
2011;6:315-9.
IF
0,364
Trends and novel approaches in neoadjuvant treatment.
Review
Breast

Care
2011;[in
press].
IF
0,364

15. BARTSCH R, ZIELINSKI CC.
Adjuvant systemic therapy for early breast cancer
Review
Emirates Journal of Medical Sciences;[in

press].
IF
n.a.

PUBLIKATIONEN (IM PEER REVIEW VERFAHREN)

Erstautor / Corresponding Author

1. BERGHOFF A, BAGO-HORVATH Z, DUBSKY P, RUDAS M, PLUSCHNIG U,
WILTSCHKE C, GNANT M, STEGER GG, ZIELINSKI CC, BARTSCH R.
Impact of her-2 – targeted therapy on overall survival in patients with her-2 positive
metastatic breast cancer.
Submitted to Breast Journal
2. BARTSCH R, BAGO-HORVATH Z, PLUSCHNIG U, DEVRIES C, BERGHOFF A,
DUBSKY P, RUDAS M, MADER RM, ROTTENFUSSER A, FITZAL F, GNANT M,
ZIELINSKI CC, STEGER GG.
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women
with metastatic breast cancer.
Submitted to European Journal of Cancer

3. BERGHOFF A, BAGO-HORVATH Z, DE VRIES C, DUBSKY P, PLUSCHNIG U,
RUDAS M, ROTTENFUSSER A, KNAUER M, EITER H, FITZAL F, DIECKMANN K,
MADER R, GNANT M, ZIELINSKI CC, STEGER GG, PREUSSER M, BARTSCH R.
Brain metastases free survival differs between breast cancer subtypes.
Submitted to British Journal of Cancer

Coautor

1. PLUSCHNIG U, HASLIK W, BAYER G, SOLEIMAN A, BARTSCH R, LAMM W,
STEGER GG, ZIELINSKI CC, MADER RM.
Extravasation of cytotoxic agents: novel aspects of diagnosis and clinical management - the
Vienna experience
Submitted to Lancet

2. ARNOLD T, MICHLMAYR A, BAUMANN A, BURGHUBER C, PLUSCHNIG U,
BARTSCH R, STEGER G, GNANT M, BERGMANN M, BACHLEITNER-HOFMANN T,
OEHLER R.
Increase in plasma HMGB-1 after initial dose of epirubicin/docetaxel in breast cancer is
associated with response to therapy.
Submitted to BMC Cancer

BUCHBEITRÄGE

1. BARTSCH R, STEGER G.
Denosumab – das Molekül: Erster klinischer Einsatz (German).
In: Gnant M, Hadji P (Eds.). Osteo-Onkologie – RANKL-Inhibition beim Mammakarzinom,
pp 50-55.
Uni-Med Verlag 2009.
2. BARTSCH R, STEGER G.
Mammakarzinom (German).
In: Marian B (Ed.). Krankheit, Krankheitsursachen und -bilder, pp 360-384.
Facultas. wuv 2010.
3. BARTSCH R, STEGER GG.
Trastuzumab as adjuvant treatment for early stage Her2-positive breast cancer.
In: Sibilia M, Zielinski CC, Bartsch R, Grunt T (Eds.). Milestones in Drug Therapy: Drugs for
HER-2-positive Breast Cancer, pp 33-50.
Springer Basel 2011.
ABSTRACTS

Erstautor / Corresponding Author

1. BARTSCH R, WENZEL C, PLUSCHNIG U, HUSSIAN D, ZIELINSKI CC, STEGER
GG. Preoperative second-line chemotherapy induces objective responses in primary breast
cancer.
ECCO 12, September 2003, Kopenhagen, Dänemark - ABSTRACT

2. BARTSCH R, HUSSIAN D, WENZEL C, PLUSCHNIG U, LOCKER G, MADER R,
ZIELINSKI CC, STEGER GG. Darbepoetin alfa in the treatment of anaemia in patients
receiving chemotherapy.
20. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO-
ASSO), September 2003, Wien, Österreich - VORTRAG

3. BARTSCH R, PLUSCHNIG U, WENZEL C, HUSSIAN D, LOCKER GJ, MADER R,
ZIELINSKI CC, STEGER GG. Oral Vinorelbine in the treatment of advanced breast cancer.
2004 Annual Meeting of the American Society of Clinical Oncology, Juni 2004, New
Orleans, USA - POSTER

4. BARTSCH R, STEGER GG, WENZEL C, PLUSCHNIG U, HUSSIAN D, SEVELDA U,
MADER R, ZIELINSKI CC. Prognostic value of tumour markers CA 15-3 and CEA during
fulvestrant treatment.
2005 Annual Meeting of the American Society of Clinical Oncology, Mai 2005, Orlando,
USA - ABSTRACT

5. BARTSCH R, WENZEL C, HUSSIAN D, KOESTLER W, PLUSCHNIG U, SEVELDA
U, LOCKER G, MADER R, ZIELINSKI CC, STEGER GG. Do HER2 positive patients
profit from continued trastuzumab treatment beyond disease progression? A single centre
experience.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2005, Oktober 2005, Hannover,
Deutschland - POSTER

6. BARTSCH R, WENZEL C, HUSSIAN D, SEVELDA U, PLUSCHNIG U, LOCKER G,
MADER R, ZIELINSKI CC, STEGER GG. Results from an observational trial of darbepoetin
alfa as treatment for anaemia in patients on chemotherapy.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2005, Oktober 2005, Hannover,
Deutschland - POSTER

7. BARTSCH R, WENZEL C, PLUSCHNIG U, HUSSIAN D, SEVELDA U, MADER R,
ZIELINSKI CC, STEGER GG. Value of tumour markers CA 15-3 and CEA in predicting
response and progression during fulvestrant treatment.
ECCO 13, Oktober 2005, Paris, Frankreich - POSTER

8. BARTSCH R, WENZEL C, HUSSIAN D, KOESTLER W, PLUSCHNIG U, SEVELDA
U, LOCKER G, MADER R, ZIELINSKI CC, STEGER GG. Analysis of trastuzumab and
chemotherapy in advanced breast cancer after the failure of at least one earlier combination:
an observational study.
ECCO 13, Oktober 2005, Paris, Frankreich - ABSTRACT

9. BARTSCH R, MUSCHITZ S, RUDAS M, WENZEL C, HARBAUER S, ROESSLER K,
STEGER GG, POETTER R, DIECKMANN K. Boost irradiation and systemic therapy
significantly increase survival in patients with brain metastases from advanced breast cancer.
Jahrestagung der österreichischen Gesellschaft für Radioonkologie 2005, Dezember 2005,
Salzburg, Österreich - VORTRAG


10. BARTSCH R, MUSCHITZ S, WENZEL C, ROESSLER K, DIECKMANN K,
WEITMANN HD, POETTER R, ZIELINSKI CC, STEGER GG. Intensified local treatment
and systemic therapy significantly increase survival in patients with brain metastases from
advanced breast cancer.
2006 Annual Meeting of the American Society of Clinical Oncology, Juni 2006, Atlanta,
USA - ABSTRACT

11. BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, MADER R, GNANT M,
JAKESZ R, RUDAS M, ZIELINSKI C, STEGER G. Das Ansprechen auf Fulvestrant ist
abhängig von der Proliferationsrate, jedoch nicht von p53, Grading, Progesteronrezeptor, und
Her2-Status.
Jahrestagung der österreichischen Gesellschaft für Senologie, September 2006, Salzburg,
Österreich - POSTER

12. BARTSCH R, WENZEL C, PLUSCHNIG U, ALTORJAI G, BACHLEITNER-
HOFMANN T, LOCKER G, RUDAS M, MADER R, ZIELINSKI C, STEGER G. Results
from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2006, Oktober 2006, Leipzig,
Deutschland - POSTER

13. BARTSCH R, WENZEL C, ALTORJAI G, LUSCHNIG U, MADER R, GNANT M,
JAKESZ R, ZIELISNKI CC, STEGER GG. High proliferation rate but not p53, grading,
progesterone receptor status, and Her2 status predicts response to fulvestrant.
29th Annual San Antonia Breast Cancer Symposium, Dezember 2006, San Antonio, Texas,
USA - POSTER

14. BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, LOCKER GJ, RUDAS M,
MADER RM, ZIELINSKI CC, STEGER GG. Trastuzumab (T) plus capecitabine (C) in
heavily pretreated patients (pts) with advanced breast cancer (ABC).
2007 Annual Meeting of the American Society of Clinical Oncology, Juni 2007, Chicago,
USA - POSTER

15. BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, LOCKER GJ, RUDAS M,
MADER RM, ZIELINSKI CC, STEGER GG. Combination of capecitabine and trastuzumab
is effective in heavily pretreated patients with metastatic breast cancer.
2007 ASCO Breast Cancer Symposium, September 2007, San Francisco, USA - POSTER
16. BARTSCH R, WENZEL C, PLUSCHNIG U, ALTORJAI G, ZIELINSKI CC, STEGER
GG. Trastuzumab-treatment beyond progression – the Vienna experience.
2007 Joint Meeting of the Slovenian and Austrian Society of Senology, September 2007,
Graz, Österreich - VORTRAG (invited)

17. BARTSCH R, WENZEL C, ALTORJAI G, PLUSCHNIG U, LOCKER GJ, RUDAS M,
MADER RM, ZIELINSKI CC, STEGER GG. Capecitabine plus trastuzumab: An effective
salvage regimen in heavily pretreated patients with metastatic breast cancer.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2007, Oktober 2007, Basel,
Schweiz - VORTRAG

18. BARTSCH R, MLINERITSCH B, GNANT M, NIERNBERGER T, PLUSCHNIG U,
GREIL R, POBER M, SEVELDA P, THALER J, STEGER GG. The Austrian fulvestrant
registry – results from a prospective observation of fulvestrant in postmenopausal patients.
2008 Annual Meeting of the American Society of Clinical Oncology, Juni 2008, Chicago,
USA - POSTER

19. BARTSCH R, WENZEL C, PULSCHNIG U, ALTORJAI G, DUBSKY P, SCHEUER R,
ROTTENFUSSER A, GNANT M, ZIELINSKI CC, STEGER GG. Combination of
trastuzumab and gemcitabine as salvage therapy in heavily pretreated patients with metastatic
breast cancer.
The 6th European Breast Cancer Conference (EBCC 6), April 2008, Berlin, Deutschland -
POSTER

20. BARTSCH R, WENZEL C, PULSCHNIG U, ALTORJAI G, DUBSKY P, SCHEUER R,
ROTTENFUSSER A, GNANT M, ZIELINSKI CC, STEGER GG. Trastuzumab and
gemcitabine in heavily pre-treated patents with metastatic breast cancer
Frühjahrstagung 2008 der ÖGHO, April 2008, Innsbruck, Österreich - VORTRAG
21. BARTSCH R, WENZEL C, GAMPENRIEDER SP, PLUSCHNIG U, BLAHA P,
ALTORJAI G, GNANT M, RUDAS M, ROTTENFUSSER A, MADER RM, ZIELINSKI
CC, STEGER GG. Oral vinorelbine in metastatic breast cancer – the Vienna experience.
2008 Jahrestagung der European Society of Medical Oncology, September 2008,
Stockholm, Schweden - POSTER

22. BARTSCH R, MLINERITSCH B, GNANT M, NIERNBERGER T, PLUSCHNIG U,
GREIL R, POBER M, THALER J, ZIELINSKI CC, STEGER GG, on behalf of the Austrian
Fulvestrant Registry. The Austrian Fulvestrant Registry: results from a prospective
observation of fulvestrant in postmenopausal patients.
2008 ASCO Breast Cancer Symposium, September 2008, Washington, USA - POSTER
23. BARTSCH R, KNAUER M, ROTTENFUSSER A, WENZEL C, DIECKMANN K,
EITER H, PLUSCHNIG U, DE VRIES A, ZIELINSKI CC, STEGER GG. Analysis of risk
factors associated with early development of brain metastases in patients with metastatic
breast cancer.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2008, Oktober 2008, Wien,
Österreich - POSTER

24. BARTSCH R, MLINERITSCH B, GNANT M, NIERNBERGER T, PLUSCHNIG U,
GREIL R, POBER M, THALER J, ZIELINSKI CC, STEGER GG, on behalf of the Austrian
Fulvestrant Registry. A prospective observation of fulvestrant in postmenopausal patients: the
Austrian Fulvestrant Registry.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2008, Oktober 2008, Wien,
Österreich - POSTER

25. BARTSCH R, DUBSKY P, JAKESZ R, STEGER GG, GNANT M. Bisphosphonates in
early breast cancer: Successes and challenges towards individualized therapy.
14th Days of Prof. Vladimira Staska Meeting, März 2009, Prag, Tschechien - VORTRAG
(invited)

26. BARTSCH R, ZIELINSKI CC, on behalf of the Consensus Participants and CECOG.
Third consensus on the medical treatment of metastatic breast cancer.
2nd Interconference Breast Cancer Meeting, April 2009, Sarajevo, Bosnien-Herzegowina -
VORTRAG (invited)

27. BARTSCH R, WENZEL C, PLUSCHNIG U, DUBSKY P, GAMPENRIEDER SP,
RUDAS M, MADER R, GNANT M, ZIELINSKI CC, STEGER GG. Predicting response to
second-line trastuzumab-based therapy in patients (pts) with her2-positive advanced breast
cancer (ABC).
2009 Annual Meeting of the American Society of Clinical Oncology, Juni 2009, Orlando,
USA
- POSTER

28. BARTSCH R, DE VRIES C, PLUSCHNIG U, DUBSKY P, HORVATH S, RUDAS M,
MADER RM, GNANT M, ZIELISNKI CC, STEGER GG. Analysis of factors predicting
response to second-line trastuzumab-based therapy in patients (pts) with Her2-positive
advanced breast cancer (ABC).
ECCO 15, September 2009, Berlin, Deutschland - POSTER

29. BARTSCH R, DE VRIES C, PLUSCHNIG U, DUBKSY P, HORVATH S, RUDAS M,
MADER R, GNANT M, ZIELINSKI C, STEGER G. Predicting for benefit from trastuzumab
in multiple lines.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2009, Oktober 2009,
Mannheim und Heidelberg, Deutschland - VORTRAG

30. BARTSCH R, DE VRIES C, KNAUER M, PLUSCHNIG U, ROTTENFUSSER A,
BAGO-HORVATH Z, DIECKMANN K, EITER H, RUDAS M, DE VRIES A, ZIELINSKI
CC, STEGER GG. Prädiktive Faktoren zum frühzeitigen Auftreten von Hirnmetastasen.
Jahrestagung der österreichischen Gesellschaft für Senologie, September 2009, Velden,
Österreich - VORTRAG

31. BARTSCH R. Targeted therapies: Enthusiastic interest, critical disappointment, renewed
appreciation.
26. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO-
ASSO), Oktober 2009, St. Wolfgang, Österreich - VORTRAG (invited)

32. BASRTCH R, KNAUER M, DE VRIES C, PLUSCHNIG U, BAGO-HORVATH Z,
GNANT M, DIECKMANN C, ZIELINSKI CC, DE VRIES A, STEGER GG. Analysis of
risk factors associated with early development of brain metastases in breast cancer.
The 7th European Breast Cancer Conference (EBCC 7), März 2010, Barcelona, Spanien -
POSTER

33. BARTSCH R, DE VRIES C, FOEDERMAYR M, PLUSCHNIG U, HUBER M, BAGO-
HORVATH Z, GIRSCHIKOFSKY M, STEGER GG, DUBSKY P, GNANT M, ZIELINSKI
CC, ZIEBERMAYR R. Metaanalyisis of survival outcomes in first-line bevacizumab.
Frühjahrstagung 2010 der ÖGHO, April 2010, Bregenz, Österreich - VORTRAG
34. BARTSCH R, DE VRIES C, ZIEBERMAYR R, BAGO-HORVATH Z, PLUSCHNIG U,
DUBSKY P, GNANT M, ZIELINSKI CC, WELTERMANN A, STEGER GG. Fulvestrant
(F) as first-line palliative treatment for ER-positive metastatic breast cancer (MBC).
2010 Annual Meeting of the American Society of Clinical Oncology, Juni 2010, Chicago,
USA - POSTER

35. BARTSCH R, DE VRIES C, FOEDERMAYR M, MADER RM, HUBER M, BAGO-
HORVATH Z, PLUSCHNIG U, STEGER GG, DUBSKY P, FITZAL F, SCHREIL G,
ZIELINSKI CC, GAMPENRIEDER P, ZIEBERMAYR R. Bevacizumab as first-line therapy
for advanced breast cancer.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2010, Oktober 2010, Berlin,
Deutschland - VORTRAG

36. BARTSCH R, BERGHOFF A, PLUSCHNIG U, BAGO-HORVATH Z, DUBSKY P,
ROTTENFUSSER A, DE VRIES C, RUDAS M, FITZAL F, DIECKMANN K, GNANT M,
ZIELINSKI CC, STEGER GG. Systemic therapy and overall survival (OS) in patients (pts)
with brain metastases from Her2-positive (Her2+) metastatic breast cancer (MBC).
2011 Annual Meeting of the American Society of Clinical Oncology, Juni 2011, Chicago,
USA - POSTER

37. BARTSCH R, BERHOFF A, PLUSCHNIG U, BAGO-HORVATH Z, DUBSKY P,
ROTTENFUSSER A, DE VRIES C, MADER R, ZIELINSKI CC, STEGER GG. Influence of
systemic therapy on overall survival in patients with brain metastases from Her2-positive
breast cancer.
Frühjahrstagung 2011 der ÖGHO, Mai 2010, Pörtschach, Österreich - VORTRAG

38. BARTSCH R.
VEGF-inhibition: Inconsistencies and failures in clinical trials.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2011, Oktober 2011, Basel,
Schweiz – VORTRAG (invited)

39. BARTSCH R, PREUSSER M, MAROSI C.
Chemotherapy for brain metastases.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2011, Oktober 2011, Basel,
Schweiz – VORTRAG (invited)

40. BARTSCH R, BERGHOFF A, PLUSCHNIG U, BAGO-HORVATH Z, DUBSKY P,
ROTTENFUSSER A, GNANT M, MADER R, ZIELINSKI CC, STEGER GG. Impact of
systemic anti-Her2 treatment on overall survival in patients with brain metastases from Her2-
overexpressing breast cancer
ECCO 16, September 2011, Stockholm, Schweden - POSTER

41. BERGHOFF A, BAGO-HORVATH Z, DUBSKY P, RUDAS M, PLUSCHNIG U,
ROTTENFUSSER A, GNANT M, STEGER GG, ZIELINSKI CC, BARTSCH R.
Brain metastases-free survival in patients with Her2-positive metastatic breast cancer.
2011 ASCO Breast Cancer Symposium, September 2011, San Francisco, USA - POSTER

42. BARTSCH R, BERGHOFF A, BAGO-HORVATH Z, DEVRIES C, DUBSKY P,
PLUSCHNIG U, RUDAS M, ROTTENFUSSER A, FITZAL F, DIECKMANN K, MADER
RM, GNANT M, ZIELINSKI CC, STEGER GG. Brain metastasis free survival (BMFS)
differs between breast cancer subtypes.
34th Annual San Antonia Breast Cancer Symposium, Dezember 2011, San Antonio, Texas,
USA – POSTER

43. BARTSCH R, BAGO-HORVATH Z, PLUSCHNIG U, BERGHOFF A, DUBSKY P,
MADER RM, FITZAL F, GNANT M, ZIELINSKI CC, STEGER GG. Ovarian function
suppression plus fulvestrant in premenopausal women with metastatic breast cancer.
Submitted to: The 8th European Breast Cancer Conference (EBCC 8), März 2012, Wien,
Österreich

Coautor

1. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, ZIELINSKI CC, STEGER
GG. Capecitabine-monotherapy and in combination with immunotherapy in the treatment of
metastatic renal cell carcinoma.
ECCO 12, September 2003, Kopenhagen, Dänemark

2. MADER R, RIZOVSKI B, WENZEL C, BARTSCH R, ZIELINSKI CC, STEGER GG.
Pharmacokinetics of epirubicin and paclitaxel during weekly administration in patients with
metastasised breast cancer.
ECCO 12, September 2003, Kopenhagen, Dänemark

3. WENZEL C, LOCKER GJ, BARTSCH R, PLUSCHNIG U, ZIELINSKI CC,
STEGER GG. Capecitabine-monotherapy and in combination with immunotherapy in the
treatment of metastatic renal cell carcinoma.
Gemeinsame Jahrestagung der DGHO, ÖGHO und SGMO, Oktober 2003, Basel, Schweiz

4. STEGER GG, WENZEL C, BARTSCH R, RUDAS M, GNANT MF, ZIELINSKI CC,
JAKESZ R. Preliminary results of a pilot-trial with trastuzumab and weekly epidoxorubicin /
docetaxel in the neoadjuvant treatment of primary, operable breast cancer.
Primary Therapy of Early Breast Cancer, 8th International Conference, März 2003, St.
Gallen, Schweiz

5. STEGER GG, BARTSCH R, WENZEL C, PLUSCHNIG U, LOCKER G, MADER RM,
ZIELINSKI CC. Fulvestrant beyond the second hormonal treatment line in metastatic breast
cancer.
2003 Annual Meeting of the American Society of Clinical Oncology, Mai 2003 Chicago,
USA

6. STEGER GG, BARTSCH R, WENZEL C, PLUSCHNIG U, LOCKER G, MADER RM,
ZIELINSKI CC. Fulvestrant (Faslodex) demonstrates clinical benefit in heavily pre-treated
patients with metastatic breast cancer.
ECCO 12, September 2003, Kopenhagen, Dänemark

7. HUSSIAN D, WENZEL C, BARTSCH R, PLUSCHNIG U, ZIELINSKI CC, STEGER
GG. Preoperative second-line chemotherapy induces objective responses in primary breast
cancer.
Gemeinsame Jahrestagung der DGHO, ÖGHO und SGMO, Oktober 2003, Basel, Schweiz

8. PLUSCHNIG U, HUSSIAN D, WENZEL C, BARTSCH R, ZIELINSKI CC, STEGER
GG. Frequency of amenorrhea induced by adjuvant chemotherapy in premenopausal breast
cancer patients induced by different chemotherapy regimen.
New developments in breast cancer, November 2003, Monaco
9. STEGER GG, BARTSCH R, WENZEL C, PLUSCHNIG U, LOCKER G, MADER RM,
ZIELINSKI CC. Fulvestrant (Faslodex) demonstrates clinical benefit in heavily pre-treated
patients with metastatic breast cancer.
26th Annual San Antonia Breast Cancer Symposium, Dezember 2003, San Antonio, Texas,
USA

10. WENZEL C, HUSSIAN D, BARTSCH R, PLUSCHNIG U, LOCKER GJ, GNANT M,
JAKESZ R, ZIELINKSI CC, STEGER GG. Feasibility of Taxotere, Epirubicin and Xeloda
(TEX) plus Pegfilgrastim as neoadjuvant treatment for primary breast cancer: a pilot study.
2004 Annual meeting of the American Society of Clinical Oncology, Juni 2004, New
Orleans, USA

11. STEGER GG, BARTSCH R, WENZEL C, HUSSIAN D, SEVELDA U, PLUSCHNIG U,
MADER R, ZIELINSKI CC. Fulvestrant (FUL) and goserelin (GOS) in premenopausal
women with advanced, hormone-sensitive breast cancer – a pilot study.
2005 Annual Meeting of the American Society of Clinical Oncology, Mai 2005, Orlando,
USA

12. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, LOCKER GJ, SEVELDA U,
ZIELINSKI CC, STEGER GG. Single administration of pegylated filgrastim once per cycle
compared to daily filgrastim in patients with primary breast cancer receiving neoadjuvant
chemotherapy.
2005 Annual Meeting of the American Society of Clinical Oncology, Mai 2005, Orlando,
USA

13. RADERER M, WOEHRER S, BARTSCH R, PRAGER G, DRACH J, HAJNA M,
GAIGER A, TURETSCHEK K, JAEGER U, ZIELINSKI CC. A phase II study of oxaliplatin
in patients with MALT-lymphoma.
2005 Symposium on Leukaemia and Lymphoma, März 2005, Amsterdam, Niederlande
14. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, SEVELDA U, ZIELISNKI
CC, STEGER GG. Pegyliertes Filgrastim (P) versus Filgrastim (F) zur Prävention von
Chemotherapie-assoziierter Neutropenie bei Patientinnen mit primären Mammakarzinom.
Gemeinsame Jahrestagung der Österreichischen, Deutschen und Schweizer Senologie
Oktober 2005, Stuttgart, Deutschland

15. HUSSIAN D, WENZEL C, SEVELDA U, BARTSCH R, PLUSCHNIG U, MADER R,
LOCKER G, GNANT M, JAKESZ R, ZIELISNKI CC, STEGER GG. Anaemia as prognostic
factor in patients with primary breast cancer after neoadjuvant chemotherapy.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2005, Oktober 2005, Hannover,
Deutschland

16. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, LOCKER G, SEVELDA U,
ZIELISNKI CC, STEGER GG. Pegylated filgrastim (P) versus filgrastim (F) in primary
prevention of chemotherapy associated neutropenia in the neoadjuvant treatment of primary
breast cancer.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2005, Oktober 2005, Hannover,
Deutschland

17. WENZEL C, HUSSIAN D, BARTSCH R, PLUSCHNIG U, SEVELDA U, LOCKER G,
GNANT M, ZIELINSKI CC, JAKESZ R, STEGER GG. Invasive ductal carcinoma and
invasive lobular carcinoma of the breast differ in response following neoadjuvant therapy
with epidoxorubicin and docetaxel+G-CSF.
ECCO 13, Oktober 2005, Paris, Frankreich

18. STEGER GG, BARTSCH R, WENZEL C, HUSSIAN D, SEVELDA U, PLUSCHNIG U,
MADER R, ZIELINSKI CC. Results from a pilot study with goserelin plus fulvestrant in
premenopausal women with advanced, hormone-sensitive breast cancer.
ECCO 13, Oktober 2005, Paris, Frankreich

19. MADER R, FORSTNER B, BARTSCH R, WENZEL C, PLUSCHNIG U, ZIELINSKI C,
STEGER G. Induction of thymidine phosphorylase by paclitaxel in patients with advanced
breast cancer.
Frühjahrstagung 2006 der ÖGHO, April 2006, Wels, Österreich

20. FROMM S, HOKE M, ROTTENFUSSER A, BARTSCH R, POTTER R, POKRAJAC B.
A retrospective analysis of survival, local control and prognostic factors in node positive
patients treated with adjuvant 3D-conformal radiotherapy.
10th Central European Lung Cancer Conference, Juni 2006, Prag, Tschechien

21. ROTTENFUSSER A, GATTERBAUER B, LEHNERT M, BARTSCH R, FROMM S,
MAROSI C, KITZ K, POETTER R, DIECKMANN K. Retrospective anlaysis of re-
irradiation in malignant glioma at the LNAC and gamma-knife: Experience at the Medical
University of Vienna.
Jahrestagung der EANO 2006, September 2006, Wien, Österreich

22. WENZEL C, BARTSCH R, HUSSIAN D, PLUSCHNIG U, ALTORJAI G, GNANT M,
ZIELINSKI C, JAKESZ R, STEGER G. Unterschiedliches Ansprechen zwischen invasiv
duktalem und lobulärem Mammakarzinom auf präoperative Chemotherapie.
Jahrestagung der österreichischen Gesellschaft für Senologie, September 2006, Salzburg,
Österreich

23. STEGER GG, GREIL R, SAMONIGG H, JAKESZ R, BARTSCH R, MLINERITSCH B,
MELBINGER-ZEINITZER E, MARTH C, SCHIPPINGER W, GNANT MF. An interim
safety analysis of ABCSG-24: 6 cycles of docetaxel, epirubicin, and capecitabine +
pegfilgrastim (DEC) vs. 6 cycles of docetaxel and epirubicin + pegfilgrastim (DE) in the
neoadjuvant treatment of operable breast cancer.
29th Annual San Antonia Breast Cancer Symposium, Dezember 2006, San Antonio, Texas,
USA

24. ALTORJAI G, BARTSCH R, WENZEL C, PLUSCHNIG U, MADER RM, GNANT M,
JAKESZ R, RUDAS M, ZIELINSKI CC, STEGER GG. Response to fulvestrant treatment is
independent of Her2 receptor status.
Frühjahrstagung 2007 der ÖGHO, April 2007, Wien, Österreich

25. STEGER GG, GREIL R, SAMONIGG H, JAKESZ R, BARTSCH R, MLINERITSCH B,
MELBINGER-ZEINITZER E, MARTH C SCHIPPINGER W, GNANT MF, Austrian Breast
and Colorectal Cancer study Group. Randomized comparison of neoadjuvant docetaxel (D),
epirubicin (E) and pegfilgrastim (P) (+ trastuzumb [T] in Her2+ patients [pts]) with and
without capecitabine (C) for operable breast cancer (BC): Results of a planned safety analysis
of ABCSG 24.
2007 Annual Meeting of the American Society of Clinical Oncology, Juni 2007, Chicago,
USA


26. FROMM S, HOKE M, ROTTENFUSSER A, BARTSCH R, POTTER R, POKRAJAC B.
A retrospective analysis of survival, local control and prognostic factors in node positive non-
small cell lung cancer patients treated with adjuvant 3D-conformal radiotherapy.
Jahrestagung der Deutschen Gesellschaft für Radioonkologie 2007, Juni 2007, Hannover,
Deutschland

27. ALTORJAI G, BARTSCH R, ROTTENFUSSER A, WENZEL C, DIECKMANN K,
PLUSCHNIG U, RUDAS M, MADER RM, POETTER R, ZIELINSKI CC, STEGER GG.
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive
breast cancer.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2007, Oktober 2007, Basel,
Schweiz

28. ROTTENFUSSER A, GATTERBAUER B, BARTSCH R, MAROSI C, KITZ K,
PÖTTER R, DIECKMANN K. Retrospektive Analyse der Re-irradiatio von Gliomen mittels
Gamma-knife und LINAC: Erfahrungen an der Medizinischen Universität Wien. Aktualisierte
Daten.
Jahrestagung der Österreichischen Gesellschaft für Radioonkologie 2007, Oktober 2007,
Graz, Österreich

29. KNAUER M, ROTTENFUSSER A, BARTSCH R, DIECKMANN K, WENZEL C,
FROMM S, EITER G, STEGER GG, ZIELINSKI CC, DE VRIES A. Analysis of risk factors
predicting time to development of brain metastases.
2008 Annual Meeting of the American Society of Clinical Oncology, Juni 2008, Chicago,
USA

30. ROTTENFUSSER A, LÜTGENDORF-CAUCIG C, ALTORJAI G STOCK M,
WINKLER P, KROUPA B, BARTSCH R, GEORG D, PÖTTER R; DIECKMANN K.
Stereotaktische Radiotherapie (SRT) zur Behandlung von Hepatozellulären Carcinomen
(HCC) - Erfahrungen an der Medizinischen Universität Wien.
Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaften für
Radioonkologie 2008, Mai 2008, Wien, Österreich

31. ROTTENFUSSER A, KNAUER M, FROMM S, BARTSCH R, EITER H, ALTORJAI G,
LÜTGENDORF-CAUCIG C, WENZEL C, PÖTTER R, DE VRIES A; DIECKMANN K.
Early development of brain metastases from breast cancer: Analysis of potential risk factors.
Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaften für
Radioonkologie 2008, Mai 2008, Wien, Österreich

32. DIECKMANN K, ROTTENFUSSER A, PREUSSER M, HASSLER M, BARTSCH R,
LÜTGENDORF-CAUCIG C, ALTORJAI G, MAROSI C, PÖTTER R. Ergebnisse von 447
kombiniert operativ und radio-chemotherapeutisch behandelten Patienten mit Glioblastom an
der Medizinischen Universität Wien.
Gemeinsame Jahrestagung der Deutschen und Österreichischen Gesellschaften für
Radioonkologie 2008, Mai 2008, Wien, Österreich

33. STEGER GG, MLINERITSCH B, BARTSCH R, GNANT M, NIERNBERGER T,
PLUSCHNIG U, GREIL R, POBER M, SEVELDA P, THALER J, ZIELINSKI CC, on
behalf of the Austrian Fulvestrant Registry. Results from the Austrian Fulvestrant Registry.
Frühjahrstagung 2008 der ÖGHO, April 2008, Innsbruck, Österreich
34. ROTTENFUSSER A, PREUSSER M, ALTORJAI G, BARTSCH R, LÜTGENDORF-
CAUZCIG C, HASSLER M, CZECH T, HAINFELLNER J, MAROSI C, POETTER R,
DIECKMANN K. Results from 447 patients treated with combined modality therapy for
glioblastoma multiforme (GBM) at the Medical University of Vienna.
2008 Annual Meeting of the European Society of Therapeutic Radiology and Oncology,
September 2008, Göteborg, Schweden

35. GAMPENRIEDER SP, BARTSCH R, PLUSCHNIG U, SCHEUER R, MATZNELLER
P, DUBSKY P, GNANT M, ZIELISNKICC, STEGER GG. An all-oral chemotherapy in
locally advanced and metastatic breast cancer.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2008, Oktober 2008, Wien,
Österreich

36. DIECKMANN K, PREUSSER M, ROTTENFUSSER A, BARTSCH R, HASSLER M,
CZECH T, HAINFELLBER J, POETTER P, MAROSI C. Combined-modality Therapy for
Glioblastoma Multiforme at the University of Vienna Austria: Results from 448 Patients.
2008 Annual Meeting of the American Society of Therapeutic Radiology and Oncology,
September Juni 2008, Boston, USA

37. WILTSCKE C, WIEDERMANN U, BARTSCH R, ZURBRIGGEN R, BRÄMSWIG K,
STEGER GG, JASINSKA J, SCHEINER O, PEHAMBERGER H, ZIELINSKI CC. A HER2
multi-peptide virosome vaccine induced HER-2 specific antibodies in patients with metastatic
breast cancer: final results of a phase I study to evaluate safety and immunogenicity.
2009 Annual Meeting of the American Association of Cancer Research, April 2009,
Denver, USA

38. PLUSCHNIG U, HASLIK W, BARTSCH R, SOLEIMAN A, WENZEL W, STEGER
GG, ZIELINSKI C, MADER RM. Das Auftreten von zwei unabhängigen
Anthrazyklinparavasaten bei einer Patientin mit Mammakarzinom: Ein Fallbericht.
Jahrestagung der österreichischen Gesellschaft für Senologie, September 2009, Velden,
Österreich

39. KIERNER K, GARTNER V, BARTSCH R, WATZKE H. Zuweisungsverhalten
österreichischer OnkologInnen zu palliativmedizinischen Einrichtungen.
40. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin, September 2009,
Wien, Österreich

40. PLUSCHNIG U, ZACHERL J, SCHOPPMANN S, RADERER M, PRAGER G,
BARTSCH R, BA-SSALAMAH A, ZIELINSKI CC, HEJNA M. Neoadjuvante Therapie des
primär operablen Magenkarzinoms mit Epirubicin / Oxaliplatin / Capecitabine (EOX).
26. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO-
ASSO), Oktober 2009, St. Wolfgang, Österreich

41. FTZAL F, MITTLBOECK M, RIEDL O, BLAHA P, STEGER G, BARTSCH R,
DUBSKY P, JAKESZ R, GNANT M. Breast conserving therapy after neoadjuvant treatment:
is it safe?
26. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO-
ASSO), Oktober 2009, St. Wolfgang, Österreich

42. RIEDL O, MITTLBOECK M, STEGER G, BARTSCH R, RUDAS M, OLUSCHNIG U,
JAKESZ R, GNANT M, FIRTAL F. Inclusion criteria for the use of neoadjuvant
chemotherapy in breast cancer.
26. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO-
ASSO), Oktober 2009, St. Wolfgang, Österreich

43. RIEDL O, MITTLBOECK M, STEGER G, BARTSCH R, RUDAS M, DUBKSY P,
JAKESZ R, GNANT M, FITZAL F. Inclusion criteria for the use of neoadjuvant
chemotherapy in breast cancer.
The 7th European Breast Cancer Conference (EBCC 7), März 2010, Barcelona, Spanien

44. FITZAL F, MITTLBOECK M, RIEDL O, BLAHA P, DUBSKY P, STEGER G,
BARTSCH R, JAKESZ R, GNANT M. Breast conserving therapy after neoadjuvant
treatment: Is it oncologic safe?
The 7th European Breast Cancer Conference (EBCC 7), März 2010, Barcelona, Spanien
45. RO J, MYUNG SK, BERTON-RIGAUD D, BARTSCH R, GNANT M, STEGER GG.
The addition of capecitabine to neoadjuvant chemotherapy for early breast cancer (EBC): a
review of clinical study data.
The 7th European Breast Cancer Conference (EBCC 7), März 2010, Barcelona, Spanien

46. PLUSCHNIG U, ZACHERL J, SCHOPPMANN S, RADERER M, PRAGER G,
BARTSCH R, BA-SSALAMAH A, LAMM W, ZIELINSKI CC, HEJNA M. Neoadjuvant
chemotherapy with epirubicin, oxaliplatin and capecitabine (EOX) for resectable gastric
cancer: A single institution experience.
2010 Annual Meeting of the American Society of Clinical Oncology, Juni 2010, Chicago,
USA

47. MADER RM, BARTSCH R, FORSTNER B, KALIPCIYAN M, STEGER GG. Efficacy
of epirubicin and docetaxel in Her2-overexpressing breast cancer cell lines.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2010, Oktober 2010, Berlin,
Deutschland

48. STEGER GG, MLINERITSCH B, BARTSCH R, PLUSCHNIG U, PETRU E,
PEINTINGER F, SEVELDA P, GREIL R. Non-pegylated liposomal doxorubicin in
metastatic breast cancer (MBC) – Results from an Austrian post marketing surveillance
programme.
Gemeinsame Jahrestagung der DGHO, ÖGHO and SGMO 2010, Oktober 2010, Berlin,
Deutschland

49. FITZAL F, MITTLBOECK M, STEGER G, BARTSCH R, RUDAS M, DUBSKY P,
RIEDL O, JAKESZ R, GNANT M. Neoadjuvant chemotherapy should also be considered for
lobular breast cancer.
St. Gallen Oncology – Primary Therapy for Early Breast Cancer 2011, März 2011, St.
Gallen, Schweiz

50. PLUSCHNIG U, ZACHERL J, SCHOPPMANN S, RADERER M, PRAGER G,
BARTSCH R, BA-SSALAMAH A, LAMM W, ZIELINSKI C, HEJNA M. Locally advanced
gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and
capecitabine (EOX).
2011 ASCO Gastrointestinal Cancers Symposium, Jänner 2011, San Francisco, USA

51. KNAUER M, BACHLEITNER-HOFMANN T, BARTSCH R, HAID A, WENZL E,
TABERNO J, ROSENBERG R, LUTKE-HOLZIK M, BIBEAU F, VAN DER HOEVEN
JJM, SALAZAR R. Gene expression profiling in colon cancer: improvement of recurrence
risk assessment.
52. Österreichischer Chirurgenkongress, Juni 2011, Wien, Österreich

52. BERGHOFF A, BARTSCH R, BAGO-HORVATH Z, DUBSKY P, RUDAS M,
PLUSCHNIG U, WILTSCHKE C, GNANT M, STEGER GG, ZIELINSKI CC. Impact of
Her2-targeted therapy on overall survival (OS) in patients (pts) with Her2-positive (Her2+)
metastatic breast cancer (MBC)
2011 Annual Meeting of the American Society of Clinical Oncology, Juni 2011, Chicago,
USA

53. BERGHOFF A, BARTSCH R, BAGO-HORVATH Z, DUBSKY P, RUDAS M,
PLUSCHNIG U, WILTSCHKE C, GNANT M, STEGER GG, ZIELINSKI CC. Impact of
Trastuzumab (T) beyond disease progression on overall survival (OS): a retrospective single-
center analysis.
Frühjahrstagung 2011 der ÖGHO, Mai 2010, Pörtschach, Österreich
54. PETRICEVIC B, LÄNGLE J, SINGER J, STEGER G, BARTSCH R, JENSEN-
JAROLIM E, BERGMANN M. Die Verwendung eines FACS-basierten Assays zur
Evaluierung der Trastuzumab-assoziierten Antikörper-vermittelte zelluläre Zytotoxizität bei
Patientinnen mit metastasiertem HER2/neu positiven Brustkrebs.
28. Jahrestagung der Österreichischen Gesellschaft für Chirurgische Onkologie (ACO-
ASSO), Oktober 2011, St. Wolfgang, Österreich

Source: http://www.brustambulanz.info/wp/wp-content/uploads/2011/12/PublikationslisteNov2011.pdf

Mono-42.p65

Economic Reforms, WTO and Indian Drugs and Pharmaceuticals Industry: Implications of Emerging Trends 1 CMDR Monograph Series No. - 42 ECONOMIC REFORMS, WTO AND INDIAN DRUGS AND PHARMACEUTICALS INDUSTRY: IMPLICATIONS OF EMERGING TRENDS* Nagesh Kumar** Jaya Prakash Pradhan** ECONOMIC REFORMS, AND HEALTH SECTOR IN INDIA United Nations Development Programme (UNDP) and Governme

Microsoft word - short term missions handbook 201

Short Term Mission Handbook Table of Contents 1. First Steps A. Prayer List B. Promoting Trip & Signing Up Team Members Fundraising D. Dividing Up Leadership E. Informational Meetings 2. Health A. Vaccinations Insurance C. Health Concerns 3. Travel / Local Transportation A. Passports & Immigration Airplane C. Public Bus V

Copyright © 2010-2014 Internet pdf articles